There is no absolute age cutoff that makes hormone replacement therapy (HRT) impossible, but there is a well-established window when the benefits are clearest and the risks are lowest: before age 60 or within 10 years of menopause. Starting after that window doesn’t automatically disqualify you, but it changes the calculus significantly, and your options narrow depending on what you’re trying to treat.
The 10-Year Window
The concept guiding most prescribing decisions today is the “window of opportunity.” Women who begin HRT before age 60, or within 10 years of their final period, see the most favorable balance of benefits to risks. In the Women’s Health Initiative trials, women in this window who took hormone therapy had a 32% reduction in coronary heart disease compared to placebo. They also had lower overall mortality rates, particularly when therapy continued for six or more years.
The North American Menopause Society’s 2022 position statement reflects this directly: for women under 60 or within 10 years of menopause with no contraindications, the benefit-risk ratio is favorable for treating hot flashes, night sweats, and preventing bone loss. Once you cross that threshold, the society states the ratio “appears less favorable” because absolute risks of heart disease, stroke, blood clots, and dementia rise.
What Changes After the Window Closes
Starting HRT more than 10 years after menopause or past age 60 doesn’t guarantee harm, but the potential benefits shrink while certain risks grow. Here’s how the picture shifts across several key areas.
Heart Disease
The data on late-start HRT and heart risk is more nuanced than many people realize. A 2025 systematic review found that the increased cardiovascular risk in women starting HRT at 60 or older was “not statistically significant” across most studies. That said, one large trial (the WISDOM study) found that women starting combined estrogen-plus-progestogen therapy an average of 14 years after menopause did face increased cardiovascular risk, especially in the early years of treatment. Among women aged 70 to 79 in the WHI trials who took combined therapy, the hazard ratio for coronary heart disease was 1.48, meaning a roughly 48% higher risk compared to placebo. For estrogen-only therapy in that same age group, the risk was essentially unchanged.
The takeaway: late initiation with combined therapy (estrogen plus a progestogen) carries more concern for the heart than estrogen alone, and risk climbs with age.
Stroke
Unlike heart disease, stroke risk from standard-dose HRT does not appear to vary based on when you start. The relative increase is about one-third regardless of timing. What does change is the absolute risk. For women under 60, that translates to roughly 2 extra strokes per 10,000 women per year of use, or about 1 additional stroke for every 1,000 women using therapy for five years. For older women, the absolute number is considerably higher because baseline stroke risk rises with age.
Dementia and Cognitive Health
Timing matters enormously for brain health. A large meta-analysis published in Frontiers in Aging Neuroscience found that women who used HRT in midlife had a 13% reduced risk of all-cause dementia and a 16% reduced risk of Alzheimer’s disease. Estrogen-only therapy started in midlife was linked to a 32% reduction in dementia risk.
The pattern reverses for late starters. Women who began HRT in late life saw a 7.5% increased risk of dementia overall, with combined estrogen-plus-progestogen therapy showing a more concerning trend of up to 32% increased risk. In randomized trials of women aged 65 and older, combined therapy raised dementia risk by 64%. One prospective study found that HRT started after age 60 doubled the risk of Alzheimer’s compared to nonusers, while early initiation cut it by more than 40%.
Bone Health
HRT is effective at preventing osteoporosis-related fractures in women under 60 or within 10 years of menopause. After that point, the International Osteoporosis Foundation considers it second-line therapy, meaning other bone-specific medications are generally preferred. It can still help bone density, but the additional risks of systemic HRT in older women usually tip the balance toward drugs designed specifically for osteoporosis.
Exceptions: Early and Premature Menopause
The rules are different if you went through menopause early. Women with premature ovarian insufficiency (menopause before age 40) or early menopause (before 45) are strongly recommended to take HRT until at least the typical age of natural menopause, around 51. This applies whether or not symptoms are present, because the prolonged estrogen deficiency raises risks for heart disease, osteoporosis, and cognitive decline that outweigh the standard concerns about HRT.
Guidelines stress that delayed initiation should be avoided in these women. If you experienced early menopause and never started HRT, the window for you may still be open well into your 50s, since the clock is measured against when a typical menopause would have occurred, not when yours did. After reaching 51, your doctor can reassess based on your individual risk profile.
Options That Remain Available at Any Age
Even when systemic HRT (pills or patches that circulate estrogen throughout the body) becomes less advisable, local vaginal estrogen remains a safe and effective option for women of any age. Vaginal dryness, painful intercourse, urinary urgency, and recurrent urinary tract infections are all symptoms of genitourinary syndrome of menopause, and they tend to worsen over time without treatment.
Low-dose vaginal estrogen works locally without raising blood hormone levels above the normal postmenopausal range. An 18-year follow-up of nurses who used vaginal estrogen found no increased risk of cardiovascular disease, cancer, or hip fracture compared to nonusers. The North American Menopause Society and the American College of Obstetricians and Gynecologists both state that low-dose vaginal estrogen can be used indefinitely, with no need for additional progesterone to protect the uterus. This is the one form of estrogen therapy where “too late” essentially does not apply.
How Delivery Method Affects Risk
If you and your doctor decide that systemic HRT is worth considering outside the ideal window, the delivery method matters. Transdermal estrogen (patches, gels, or sprays absorbed through the skin) bypasses the liver, which is where oral estrogen triggers the production of clotting factors. A systematic review found that the clearest safety difference between oral and transdermal HRT is the risk of blood clots: oral estrogen raises it, while transdermal estrogen does not appear to. For a woman over 60 who might be a candidate for HRT, the transdermal route reduces at least one significant risk.
The two routes performed similarly for bone density, blood sugar regulation, and cholesterol levels. Evidence on whether they differ for breast cancer or cardiovascular disease is still inconclusive.
What Screening Looks Like for Late Starters
When a woman outside the optimal window wants to start HRT, a thorough cardiovascular risk assessment is the starting point. This means evaluating blood pressure, cholesterol, blood sugar, smoking status, weight, and family history of heart disease. European cardiology guidelines emphasize that blood pressure and cholesterol should be well controlled before HRT is considered.
For women deemed moderate risk, monitoring becomes more intensive: blood pressure, lipids, and glucose checks every three to six months rather than annually. The decision to prescribe is individualized, weighing the severity of symptoms against the specific risks that apply to you. A woman at 62 with no cardiovascular risk factors, a healthy weight, and debilitating hot flashes is in a very different position than a woman at 62 with high blood pressure and a family history of stroke.